This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Zogenix's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Second, we’ll be moving forward with the pre-approval and pre-launch preparations for Zohydro ER, and pending approval, launch the first and only single entity extended release formulation of hydrocodone in the second quarter of 2013.

Third, to complete our Relday study by year end and assuming it demonstrates safety and long-acting therapeutic PK profile, we’ll leverage the study results to potentially enter a rest of world partnership that will support the remaining Relday product development while retaining US rights.

Then fourth, to continue advancing our early stage new product opportunities including through our DosePro technology marketing partnership with Battelle. With a strengthened balance sheet and adequate capital to execute our business plans, we are very pleased with our progress and believe we are now well-positioned to continue building value for our shareholders.

Now let me update you on SUMAVEL DosePro results and initiatives including progress with a co-promotion partner along with some brief comments on our strategy for Zohydro and Relday.

On SUMAVEL for the second quarter 2012, we drove over 20,000 total prescriptions in the quarter up 16% over the second quarter of the previous year without a co-promotion effort in the second quarter, total prescriptions were down only 6% from the first quarter of 2012 with the two key components being the Zogenix sales force increased total prescriptions by 6% from all physicians we now call on, including the specific primary care physicians transferred to our team for a total of 16,000 prescriptions generated by our team in the second quarter.

In this quarter, which was the first time without a co-promotion effort, we did see a decline in prescriptions for those primary care physicians which Zogenix was not calling on. We continue to see a strong refill rate of 43% compared to 39% in the previous quarter. We reported net product revenue from sales of SUMAVEL DosePro of $8 million which includes the impact of recording $630,000 increase in the reserve for future product returns in the second quarter.

Read the rest of this transcript for free on

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 0.21%
FB $116.73 0.00%
GOOG $691.02 0.00%
TSLA $247.54 -0.07%
YHOO $36.59 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs